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Introduction 
Fingolimod is a sphingosine-1-phosphate receptor 
modulator approved for use in relapsing–remitting 
multiple sclerosis (MS). It inhibits normal egress of 
lymphocytes from lymphoid tissue and it has been 
associated with an increased risk of infection and 
lymphoma because of some of these 
immunoregulatory effects [1]. 
We report a patient with primary cutaneous Epstein-
Barr virus (EBV)-positive diffuse large B-cell 
lymphoma (DLBCL) who was taking fingolimod for 
relapsing–remitting MS. To our understanding, only 
one other incidence of EBV-positive DLBCL has been 
reported in a patient on fingolimod and that 
lymphoma, presented in the brain [2]. 
 
Case Synopsis 
A 55-year-old man with relapsing-remitting MS 
presented to the dermatology clinic in July 2016 with 
a two-month history of skin lesions on the left temple 
and cheek. His MS was managed for four years with 
interferon beta-1a but because of flu-like symptoms 
his treatment was changed to fingolimod in March 
Abstract 
A 55-year-old man with relapsing-remitting multiple 
sclerosis on fingolimod presented to the 
dermatology clinic with skin lesions on the left 
temple and cheek. Histopathology showed a diffuse 
infiltrate of enlarged, atypical lymphocytes 
throughout the dermis with an overlying grenz zone 
and a subpopulation of scattered smaller 
lymphocytes and plasma cells. Epstein-Barr virus-
encoded RNA in situ hybridization stain was positive. 
Based on the morphologic and immunophenotypic 
findings, a diagnosis of EBV-positive diffuse large B-
cell lymphoma was made. This case aims to raise 
awareness for the dermatologist that patients on 
fingolimod may be at increased risk of 
lymphoproliferative disorders. 
Figure 1. Two violaceous nodules on the temple and cheek. The 
inferior lesion is blanched in photo, which was taken after this 
lesion was anesthetized with lidocaine with epinephrine.
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2015. His subsequent course was complicated by 
herpes zoster involving the left side of his face in 
December 2015, which was treated with acyclovir.  
On physical examination, two violaceous, 
telangiectatic, nodules were present on the left 
temple, measuring 1.2cm and left cheek, measuring 
<1cm (Figure 1). A punch biopsy of each lesion was 
obtained. 
Histopathology revealed similar findings in both 
specimens, showing a diffuse infiltrate of enlarged, 
atypical lymphocytes throughout the dermis, with 
an overlying grenz zone and without epidermal 
involvement. There was a subpopulation of  
scattered smaller lymphocytes and plasma cells 
(Figures 2, 3). The large, atypical cell population 
stained positively with CD20, CD30, and BCl-6, 
whereas BCl-2 showed weak, patchy positivity 
(Figure 4). Multiple myeloma oncogene 1 and c-Myc 
were positive in about 20% of cells; Ki-67 stained 
over 90% of the large cells. The atypical cells were 
negative for CD10, CD3, CD5, CD34, and Tdt. Epstein-
Barr virus-encoded RNA in situ hybridization stain 
(EBER-ISH) was positive for EBV (Figure 4). Plasma 
EBV PCR was undetectable. Based on the 
morphologic and immunophenotypic findings, a 
diagnosis of EBV-positive diffuse large B-cell 
lymphoma was made. 
Complete blood count was normal other than 
elevated peripheral monocytes (19.5%; reference 
range 3.5-9.0) and decreased peripheral 
lymphocytes (9.5%; reference ranges 18.0-42.). 
Positron emission topography showed a 1.1cm 
subcutaneous nodule along the left temporal scalp, 
corresponding to the previously noted cutaneous 
lesion. There was no evidence of metastatic disease. 
Fingolimod was discontinued in September 2016 
and the patient was treated with three cycles of 
modified CH(O)P (cyclophosphamide, adriamycin, 
and prednisone) followed by 36Gy radiation in 18 
fractions over 30 days. Vincristine was not used 
owing to his history of MS and rituximab was 
deemed inappropriate because of a positive 
antibody titer for JC virus and a prior JC DNA titer of 
Figure 2. Skin biopsy demonstrating a diffuse infiltrate of small 
lymphocytes, larger atypical lymphocytes, and sparing of the 
epidermis with an overlying grenz zone. H&E, 50×. 
Figure 3. High magnification demonstrating both small 
lymphocytes, as well as scattered large atypical lymphocytes with 
convoluted nuclei and distinct nucleoli. H&E, 400×. 
Figure 4. Large atypical cells positive (blue stain) for EBV-
encoded RNA in-situ hybridization stain. EBER-ISH, 200×.
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1.56. JC virus is a polyomavirus present in the 
majority of the population that can reactivate in 
cases of profound immunosuppression and cause a 
devastating leukoencephalopathy. A post-treatment 
PET in November 2016 showed a complete response. 
He remains in clinical remission, Table 1. 
 
Case Discussion 
Epstein-Barr virus-positive DLBCL is one of several 
EBV-associated lymphoproliferative disorders [3]. 
Lymph node involvement occurs in up to 70% of 
patients and primary or secondary extranodal 
disease may involve the skin and soft tissue, bone 
and bone marrow, nasal and oropharyngeal cavities, 
lung, tonsils, and gastrointestinal system [3]. 
Owing to its broad immunomodulatory effects, 
fingolimod may increase the risk of certain 
infections. In clinical trials with fingolimod, the most 
commonly reported adverse events were upper 
respiratory tract infections, nasopharyngitis, and 
sinusitis. Bronchitis, influenza, and herpes viral 
infections occurred more frequently in patients 
treated with fingolimod versus placebo [1, 4]. Several 
incidences of reactivation of latent viral infections 
during fingolimod treatment have been reported, 
including hepatitis C, EBV, and varicella zoster virus 
[5, 6]. It is currently recommended that varicella 
zoster virus titers be checked and that patients with 
low titers be immunized prior to initiation of 
treatment [7]. Relevant to dermatologic care of 
patients on fingolimod, basal cell carcinoma was 
reported with higher incidence than placebo in a 
randomized controlled trial studying fingolimod for 
MS, with a relative risk of 3.9 [1]. 
Furthermore, numerous cases of lymphoma and 
lymphoproliferative disorders in patients taking 
fingolimod have been reported, including the 
aforementioned EBV-positive B-cell lymphoma of 
the brain [2]. Whereas that case of EBV-positive B-cell 
lymphoma in a patient on fingolimod presented in 
the brain in a 42-year-old man who had received nine 
months of continuous fingolimod therapy, the case 
reported herein presented after 16 months of 
fingolimod exposure while the patient was still 
receiving treatment and with disease limited to the 
skin. The diagnosis in the former case was made at 
autopsy, approximately one year after discontinuing 
fingolimod owing to a serious MS relapse. In the 
present case, remission of the cutaneous lymphoma 
was achieved with drug cessation followed by 
lymphoma treatment. 
 
Conclusion 
Herein we report a case of primary cutaneous EBV-
associated DLBCL occurring in association with 
fingolimod use. Given the recognized link between 
fingolimod and skin cancers, dermatologic 
monitoring is warranted. This case aims to raise 
awareness for the dermatologist that these patients 
may also be at increased risk of lymphoproliferative 
disorders [1, 7, 8]. We also hope this will serve as a 
reminder that fingolimod has numerous 
immunomodulatory actions, which raise the risk of 
varicella zoster virus, among other infections. 
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Table 1 Comparison of two cases of EBV-positive DLBCL associated with fingolimod use. 
  Age Sex Race Duration on fingolimod Treatment Response 
Our patient 55 Male Caucasian 16 months None (Diagnosed at autopsy) N/A 
CNS lymphoma 
patient 42 Male Unknown 9 months Modified R-CH(O)P 
Complete clinical 
remission 
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